Risk-adapted biopsy decision based on prostate MRI and PSA-density for enhanced biopsy avoidance in first prostate cancer diagnostic work-up.

Prostate MRI has been integrated into the diagnostic work-up for men at risk of having clinically significant cancer in multiple clinical care guidelines. Owing to the low false-negative rate of prostate MRI accompanying a sensitivity averaging 91%, we can reduce biopsies (by 30%) and indolent cancer detection, while maintaining (or even improving) detection of significant cancers, compared to systematic biopsy.

BJU international. 2020 Oct 21 [Epub ahead of print]

Ivo G Schoots, Anwar R Padhani

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, United Kingdom.